Chan Chee M, Woods Christian J, Warkentin Theodore E, Sheppard Jo-Ann I, Shorr Andrew F
Pulmonary and Critical Care Section, MedStar Washington Hospital Center, and Georgetown University Medical Center, Washington, DC.
Pulmonary and Critical Care Section, MedStar Washington Hospital Center, and Georgetown University Medical Center, Washington, DC.
Chest. 2015 Jul;148(1):55-61. doi: 10.1378/chest.14-1417.
Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin utilization. An enzyme-linked immunosorbent assay (ELISA) is usually performed to assist in the diagnosis of HIT. ELISAs tend to be sensitive but lack specificity. We sought to use a new cutoff to define a positive HIT ELISA.
We conducted a prospective observational study of hospitalized patients undergoing ELISA testing. All patients who underwent ELISA testing were eligible for inclusion (n = 496). Irrespective of the results, all subjects had confirmatory testing with a serotonin release assay (SRA). We compared a threshold optical density (OD) > 1.00 to the current definition of a positive ELISA (OD > 0.40) as a screening test for a positive SRA. We used sensitivity, specificity, and area under the receiver operating curve to determine whether an OD > 1.00 would improve diagnostic accuracy for HIT.
The SRA was positive in 10 patients (prevalence, 2.0%). Adjusting the definition of a positive HIT ELISA to > 1.00 maintained the sensitivity and negative predictive value at 100% in the cohort. The positive predictive value of the higher cutoff OD was more than triple the positive predictive value of an OD > 0.40 (41.7% vs 13.3%). No patient with a positive SRA had an OD measurement ≤ 1.00.
Increasing the OD threshold enhances specificity without noticeably compromising sensitivity. Altering the definition of the HIT ELISA could prevent unnecessary testing and/or treatment with non-heparin-based anticoagulants in patients with possible HIT.
ClinicalTrials.gov; No.: NCT00946400; URL: www.clinicaltrials.gov.
肝素诱导的血小板减少症(HIT)是肝素使用过程中的一种严重并发症。通常采用酶联免疫吸附测定(ELISA)来辅助诊断HIT。ELISA往往具有敏感性,但缺乏特异性。我们试图采用一个新的临界值来定义ELISA检测HIT阳性。
我们对接受ELISA检测的住院患者进行了一项前瞻性观察研究。所有接受ELISA检测的患者均符合纳入标准(n = 496)。无论检测结果如何,所有受试者均采用5-羟色胺释放试验(SRA)进行确诊检测。我们将光密度(OD)> 1.00这一临界值与目前ELISA检测阳性的定义(OD > 0.40)进行比较,作为SRA检测阳性的筛查试验。我们采用敏感性、特异性和受试者操作特征曲线下面积来确定OD > 1.00是否能提高HIT的诊断准确性。
10例患者的SRA检测呈阳性(患病率为2.0%)。将HIT ELISA检测阳性的定义调整为> 1.00时,该队列的敏感性和阴性预测值维持在100%。较高临界值OD的阳性预测值是OD > 0.40时阳性预测值的三倍多(41.7%对13.3%)。没有一例SRA检测呈阳性的患者OD测量值≤ 1.00。
提高OD临界值可增强特异性,且不会显著降低敏感性。改变HIT ELISA检测的定义可避免对可能患有HIT的患者进行不必要的检测和/或使用非肝素类抗凝剂进行治疗。
ClinicalTrials.gov;编号:NCT00946400;网址:www.clinicaltrials.gov。